Improving immune response against triple negative breast cancer
Official title: Enhancing Tumor Cell Immunogenicity using Improved Molecules Targeting Chromatin Remodeling
Funded at Virginia Commonwealth University · NIH-11000795 · Data updated 2026-11-12
This study is exploring a new way to help the immune system fight advanced triple negative breast cancer by using a mix of treatments that target specific proteins and genes, and it's being tested in mice to see how well it works.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | December 13, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $181,332 |
| NIH project number | 5R21CA277437-02 |
| Project ID | NIH-11000795 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with advanced stage triple negative breast cancer who are seeking new treatment options.
✕Less likely to help
Patients with early-stage breast cancer or those with other types of cancer may not benefit from this specific research.
What this research studies
This research investigates a new approach to enhance the immune response against advanced stage triple negative breast cancer (TNBC) by combining specific chemotherapies with targeted therapies that affect chromatin remodeling. The study focuses on inhibiting a protein called BPTF, which plays a role in regulating gene expression, to boost the immunogenicity of tumor cells. By using a combination of BPTF inhibition and a DNA methyl transferase inhibitor, researchers aim to stimulate the immune system to better recognize and attack TNBC cells. This approach is being tested in mouse models to evaluate its effectiveness in controlling tumor growth.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced triple negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in enhancing tumor immunogenicity through similar approaches, indicating potential for success in this novel combination therapy.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Landry, Joseph William — Virginia Commonwealth University
- Study coordinator: Landry, Joseph William
Related research
Other NIH-funded projects on the same topics.
-
Healthy Communities for Youth: Preventing Youth Violence in Richmond and Beyond
A community-centered program to reduce youth violence in Richmond, VA and similar communities by pairing youth voices, hospital-based support, and capacity-building for local groups.
-
S1P-S1PR1: How brain cells talk to each other during development
A study at Virginia Commonwealth University will look at how brain support cells called astrocytes communicate with neurons to shape brain circuits in development.
-
Leader cell mechanics drive collective tumor invasion in breast cancer
A small grant is funding research to understand how leader cancer cells at the edge of a tumor sense their environment and drive groups of cancer cells to invade, which could reveal new ways to stop metastasis in breast cancer.
-
How itch-sensing nerves affect skin defense against parasites
Scientists want to see if itching nerves in the skin influence how the body fights skin-hugging parasites like Schistosoma mansoni.
-
VA-ACCERT Center: Transforming Cancer Control in Virginia's public housing communities
A team at Virginia universities partners with public housing programs to spread proven ways to prevent cancer and improve cancer health in low-income communities.
-
PROMINENT cancer research: understanding how mutations in normal tissue relate to cancer growth
A cancer research project at a major university is exploring how DNA mutations in normal cells relate to the development of cancer, using animal models and human tissues to uncover clues that could inform prevention and treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.